Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NCD opened for CardioDynamics

This article was originally published in The Gray Sheet

Executive Summary

Firm hopes CMS will expand coverage of its thoratic electrical bioimpedance (TEB) devices for the management of all patients with hypertension. Coverage for the management of drug-resistant hypertension, defined by non-response to three or more medications, is at the discretion of local contractors, while other forms of hypertension are non-covered. CardioDynamics cites recent data from its multi-centered, randomized CONTROL trial as evidence that its BioZ impedance cardiography technology leads to greater reduction in blood pressure than standard care (1"The Gray Sheet" July 4, 2005, p. 15). An initial comment period on the decision ends March 30, with a proposed decision due by Aug. 28...

You may also be interested in...



Comments for CardioDynamics NCD

Firm finds physician support in the majority of more than 200 comments submitted during the initial comment period, ended March 30, on expanded national coverage for its BioZ impedance cardiography technology. CardioDynamics is seeking coverage for the test's management of all patients with hypertension (1"The Gray Sheet" March 6, 2006, In Brief). The firm notes that results of its CONTROL trial supporting this indication have been published since CMS opened the decision. Robert Streimer, deputy director at CMS' Office of Clinical Standards & Quality until 2004, claims the original limited coverage decision for the technology was pushed through by former California congressman Randy "Duke" Cunningham and recommends either totally withdrawing coverage for BioZ or reducing the product's payment. CMS' proposed coverage decision is due Aug. 28...

Cardiodynamics Restructures Operations, Aspires To Return Of Profitability

Cardiodynamics is considering partnering or merging with another non-invasive cardiovascular diagnostics firm to improve its distribution presence in the physician office market

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel